Usana Health Sciences price to sales ratio USNA

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 0.3×
10-year median: 1.3×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.3× to 2.9×
Peer median: 1.8×

Usana Health Sciences' price to sales ratio is 0.3× as of Oct 23, 2026.

That is below its ten-year median of 1.3×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.3× in Aug 2026 to 2.9× in Jul 2018.

The median for 8 chemicals stocks of a similar size is 1.8×.

Price to sales ratio over time

median 1.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.3×	0.3×	0.5×
2025	0.4×	0.4×	0.8×
2024	0.8×	0.7×	1.0×
2023	1.1×	0.9×	1.3×
2022	1.0×	0.9×	1.6×
2021	1.6×	1.4×	1.9×
2020	1.5×	1.0×	1.8×
2019	1.6×	1.2×	2.5×
2018	2.4×	1.7×	2.9×
2017	1.7×	0.7×	1.7×
2016	0.8×	0.7×	1.8×
2015	1.8×	1.6×	2.5×
2014	1.7×	1.2×	2.0×
2013	1.5×	0.8×	1.8×
2012	0.7×	0.7×	1.2×

Against its peers

Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.

Company	Price to sales ratio
USNAUsana Health Sciences	0.3×
NAGENiagen Bioscience	1.5×
FTLFFitlife Brands	0.8×
FTKFlotek Industries	3.0×
CRONCronos	6.9×
BTMDbiote	0.2×
ROGRogers	2.7×
NGVTIngevity	2.1×
IOSPInnospec	1.3×
Peer median	1.8×

Where Usana Health Sciences ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Usana Health Sciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.